PL210157B1 - Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera - Google Patents

Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera

Info

Publication number
PL210157B1
PL210157B1 PL356798A PL35679801A PL210157B1 PL 210157 B1 PL210157 B1 PL 210157B1 PL 356798 A PL356798 A PL 356798A PL 35679801 A PL35679801 A PL 35679801A PL 210157 B1 PL210157 B1 PL 210157B1
Authority
PL
Poland
Prior art keywords
ser
val
xaa
gly
antibody
Prior art date
Application number
PL356798A
Other languages
English (en)
Polish (pl)
Other versions
PL356798A1 (en
Inventor
David M. Holtzman
Ronald Demattos
Kelly R. Bales
Steven M. Paul
Naoya Tsurushita
Maximiliano Vasquez
Original Assignee
Lilly Co Eli
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL210157(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Univ Washington filed Critical Lilly Co Eli
Publication of PL356798A1 publication Critical patent/PL356798A1/xx
Publication of PL210157B1 publication Critical patent/PL210157B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL356798A 2000-02-24 2001-02-26 Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera PL210157B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18460100P 2000-02-24 2000-02-24
US25446500P 2000-12-08 2000-12-08
US25449800P 2000-12-08 2000-12-08

Publications (2)

Publication Number Publication Date
PL356798A1 PL356798A1 (en) 2004-07-12
PL210157B1 true PL210157B1 (pl) 2011-12-30

Family

ID=27391859

Family Applications (2)

Application Number Title Priority Date Filing Date
PL356798A PL210157B1 (pl) 2000-02-24 2001-02-26 Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera
PL386125A PL218883B1 (pl) 2000-02-24 2001-02-26 Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL386125A PL218883B1 (pl) 2000-02-24 2001-02-26 Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera

Country Status (31)

Country Link
US (4) US7195761B2 (enExample)
EP (4) EP3150633A1 (enExample)
JP (2) JP4738696B2 (enExample)
KR (1) KR100767146B1 (enExample)
CN (3) CN1426423B (enExample)
AT (1) ATE279442T1 (enExample)
AU (1) AU4178601A (enExample)
BR (1) BRPI0108676B8 (enExample)
CA (1) CA2400559C (enExample)
CY (1) CY1118381T1 (enExample)
CZ (2) CZ304211B6 (enExample)
DE (2) DE1257584T1 (enExample)
DK (2) DK1257584T4 (enExample)
DZ (1) DZ3295A1 (enExample)
EA (1) EA006606B1 (enExample)
ES (2) ES2184660T5 (enExample)
HR (2) HRP20080430B1 (enExample)
HU (2) HUP0204074A3 (enExample)
IL (3) IL151378A0 (enExample)
LT (1) LT1481992T (enExample)
MX (1) MXPA02008145A (enExample)
NO (2) NO329840B1 (enExample)
NZ (1) NZ520800A (enExample)
PL (2) PL210157B1 (enExample)
PT (2) PT1257584E (enExample)
SI (2) SI1481992T1 (enExample)
SK (2) SK288723B6 (enExample)
TR (1) TR200202799T3 (enExample)
UA (1) UA75881C2 (enExample)
WO (1) WO2001062801A2 (enExample)
ZA (1) ZA200206712B (enExample)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2312348T3 (es) 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE420114T1 (de) * 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US20020197258A1 (en) * 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
DE60226036T9 (de) † 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
JP2005503789A (ja) * 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
ATE381346T1 (de) * 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
CA2452104A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003090772A1 (en) * 2002-04-25 2003-11-06 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7736644B2 (en) 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR101139103B1 (ko) * 2003-09-12 2012-07-05 아피리스 아게 아페레시스 장치
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US7848543B2 (en) * 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
PL1720909T3 (pl) * 2004-02-23 2012-04-30 Lilly Co Eli Przeciwciało anty-abeta
EP1741783A4 (en) * 2004-04-27 2009-05-27 Chemo Sero Therapeut Res Inst HUMAN ANTIAMYLOID BETA PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF
AU2005269940A1 (en) * 2004-07-02 2006-02-09 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta)
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
US7807804B2 (en) * 2004-10-05 2010-10-05 Wyeth Llc Methods and compositions for improving recombinant protein production
US9907485B2 (en) * 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US9924888B2 (en) * 2004-10-15 2018-03-27 Brainlab Ag Targeted infusion of agents against parkinson's disease
US9901413B2 (en) * 2004-10-15 2018-02-27 Brainlab Ag Targeted infusion of agents for treatment of ALS
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP1827493A4 (en) * 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ES2402650T3 (es) 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
KR101906161B1 (ko) * 2005-11-30 2018-10-11 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
AU2006326301B2 (en) 2005-12-12 2011-04-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
SI1996621T1 (sl) * 2006-03-30 2010-04-30 Glaxo Group Ltd Protitelesa proti amiloidnemu peptidu beta
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
EP3988566A1 (en) * 2006-07-14 2022-04-27 AC Immune SA Humanized antibody against amyloid beta
NO348280B1 (no) * 2006-07-14 2024-11-04 Genentech Inc Humanisert antistoff
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
ME01075B (me) * 2006-07-14 2012-10-20 Ac Immune Sa Antitijela
DK2074145T5 (en) * 2006-10-02 2017-10-16 Ac Immune Sa HUMANIZED ANTIBODY AGAINST AMYLOID BETA
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
ES2535641T3 (es) 2007-01-18 2015-05-13 Eli Lilly & Company Amiloide beta Fab pegilado
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2008144232A2 (en) 2007-05-18 2008-11-27 The Johns Hopkins University A treatment simulator for brain diseases and method of use thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TWI557136B (zh) * 2007-06-12 2016-11-11 Ａｃ免疫公司 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
KR20100074181A (ko) * 2007-09-13 2010-07-01 델레넥스 쎄라퓨틱스 아게 β-아밀로이드 펩티드에 대한 인간화 항체
SI2238166T1 (sl) 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
ES2639016T3 (es) * 2007-11-16 2017-10-25 The Rockefeller University Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8815794B2 (en) 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8614297B2 (en) * 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
MX2012006512A (es) 2009-12-11 2012-08-17 Araclon Biotech Sl Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.
WO2011109246A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
RU2628703C2 (ru) * 2011-12-22 2017-08-21 Ф. Хоффманн-Ля Рош Аг Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
AU2013287119A1 (en) * 2012-07-03 2015-01-22 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP4324480A3 (en) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
AR097651A1 (es) 2013-09-13 2016-04-06 Genentech Inc Métodos y composiciones que comprenden polipéptidos recombinantes purificados
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EA031419B1 (ru) 2014-04-01 2018-12-28 Пфайзер Инк. ХРОМЕН И 1,1a,2,7b-ТЕТРАГИДРОЦИКЛОПРОПА[c]ХРОМЕН ПИРИДОПИРАЗИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРА ГАММА-СЕКРЕТАЗЫ
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
ES2848376T3 (es) 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
UA125334C2 (uk) 2015-06-17 2022-02-23 Пфайзер Інк. Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази
CN107849125A (zh) * 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017075119A1 (en) 2015-10-28 2017-05-04 The Trustees Of The Univeresity Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
HK1259324A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β表位及其抗体
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
HUE048658T2 (hu) 2016-02-23 2020-07-28 Pfizer 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazin-2-karboxamid vegyületek
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
US20200055917A1 (en) 2016-09-27 2020-02-20 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
JP7236737B2 (ja) 2016-10-28 2023-03-10 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US11161844B2 (en) 2017-03-10 2021-11-02 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
SG10202110112TA (en) 2017-03-10 2021-10-28 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
SG11201913014YA (en) 2017-06-22 2020-01-30 Pfizer Dihydro-pyrrolo-pyridine derivatives
CN111093692A (zh) 2017-06-29 2020-05-01 纽约哥伦比亚大学理事会 治疗淀粉样沉积疾病的嵌合抗体
WO2019014768A1 (en) 2017-07-18 2019-01-24 The University Of British Columbia ANTI-BETA-AMYLOID ANTIBODY
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION
RU2020114641A (ru) 2017-09-26 2021-10-27 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов и способы применения
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US20200330592A1 (en) * 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
CN112154145B (zh) 2018-03-23 2023-10-17 辉瑞大药厂 哌嗪氮杂螺衍生物
EP3774864A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
US20210309726A1 (en) * 2018-05-21 2021-10-07 New York University Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
FR3091999A1 (fr) * 2019-01-25 2020-07-31 Mexbrain Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CA3186614A1 (en) 2020-07-23 2022-01-27 Michael SKOV Anti-abeta antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022182658A1 (en) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Lilly Co Eli Regional tau imaging for diagnosing and treating alzheimer's disease
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
FR2608669A1 (fr) 1986-12-19 1988-06-24 Boussois Sa Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
PT667959E (pt) * 1992-10-26 2003-12-31 Lilly Co Eli Metodos para identificar inibidores da producao do peptido beta-amiloide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
CA2171553A1 (en) * 1993-09-28 1995-04-06 Charles A. Marotta Using antisense oligonucleotides to modulate nerve growth and to reverse .beta./a4 amyloid-induced morphology
EP0802797A1 (en) * 1994-02-03 1997-10-29 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2001512689A (ja) * 1997-08-11 2001-08-28 カイロン コーポレイション Ｔ細胞を遺伝子改変するための方法
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU4007599A (en) 1998-05-21 1999-12-06 University Of Tennessee Research Corporation, The Methods for amyloid removal using anti-amyloid antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2312348T3 (es) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
CA2381323C (en) 1999-08-04 2009-10-06 University Of Southern California Amyloid .beta. protein (globular assembly and uses thereof)
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
EP3150633A1 (en) * 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU9063801A (en) 2000-09-06 2002-03-22 Aventis Pharma Sa Methods and compositions for diseases associated with amyloidosis
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE381346T1 (de) 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit

Also Published As

Publication number Publication date
HK1048640B (en) 2005-04-01
EP1257584B2 (en) 2013-03-06
UA75881C2 (en) 2006-06-15
MXPA02008145A (es) 2004-04-05
CN101670105A (zh) 2010-03-17
NO20023957L (no) 2002-10-22
NO337363B1 (no) 2016-03-29
US7892545B2 (en) 2011-02-22
KR100767146B1 (ko) 2007-10-15
LT1481992T (lt) 2017-02-10
HUP0204074A3 (en) 2004-07-28
DE1257584T1 (de) 2003-05-28
ES2184660T3 (es) 2005-05-01
BR0108676A (pt) 2003-01-07
IL151378A0 (en) 2003-04-10
KR20020089359A (ko) 2002-11-29
CA2400559C (en) 2012-05-01
EP1481992B1 (en) 2016-11-02
HRP20080430A2 (en) 2008-11-30
US20040043418A1 (en) 2004-03-04
BRPI0108676B8 (pt) 2021-05-25
DK1257584T4 (da) 2013-03-25
EP3150633A1 (en) 2017-04-05
EP1257584A2 (en) 2002-11-20
CZ2008595A3 (cs) 2017-05-03
WO2001062801A3 (en) 2002-01-31
PL356798A1 (en) 2004-07-12
JP4738696B2 (ja) 2011-08-03
SI1257584T1 (en) 2005-04-30
EP3070100B1 (en) 2021-07-07
DE60106394T2 (de) 2006-03-09
PT1481992T (pt) 2017-01-02
SK288723B6 (sk) 2020-01-07
EA006606B1 (ru) 2006-02-24
JP2009046497A (ja) 2009-03-05
EP1481992A2 (en) 2004-12-01
ZA200206712B (en) 2003-11-21
CZ304211B6 (cs) 2014-01-08
US20060039906A1 (en) 2006-02-23
US7195761B2 (en) 2007-03-27
SI1257584T2 (sl) 2013-07-31
SK288711B6 (sk) 2019-11-05
CN1426423B (zh) 2010-05-12
BRPI0108676B1 (pt) 2015-09-15
ATE279442T1 (de) 2004-10-15
EA200200897A1 (ru) 2003-02-27
PT1257584E (pt) 2005-01-31
ES2184660T5 (es) 2013-05-09
PL218883B1 (pl) 2015-02-27
NZ520800A (en) 2004-04-30
DK1481992T3 (en) 2017-01-30
DK1257584T3 (da) 2005-01-17
EP1257584B1 (en) 2004-10-13
NO20023957D0 (no) 2002-08-20
CY1118381T1 (el) 2017-06-28
TR200202799T3 (tr) 2003-03-21
EP1257584B9 (en) 2004-12-01
HRP20080430B1 (hr) 2016-12-16
HU230768B1 (hu) 2018-03-28
DE60106394T3 (de) 2013-07-25
HUP0204074A2 (hu) 2003-03-28
AU4178601A (en) 2001-09-03
DE60106394D1 (de) 2004-11-18
US8591894B2 (en) 2013-11-26
HK1048640A1 (en) 2003-04-11
WO2001062801A2 (en) 2001-08-30
HRP20080430A9 (en) 2009-02-28
US20110158986A1 (en) 2011-06-30
ES2611427T3 (es) 2017-05-08
HRP20020693B1 (hr) 2012-01-31
IL151378A (en) 2010-04-29
HRP20020693A2 (en) 2004-12-31
ES2184660T1 (es) 2003-04-16
JP2003523764A (ja) 2003-08-12
DZ3295A1 (fr) 2001-08-30
HUP0800571A2 (en) 2003-03-28
NO329840B1 (no) 2011-01-10
EP1481992A3 (en) 2004-12-08
CN1426423A (zh) 2003-06-25
NO20083805L (no) 2002-10-22
SK12212002A3 (sk) 2003-10-07
CN101670105B (zh) 2014-08-06
CZ20022851A3 (cs) 2003-09-17
SI1481992T1 (sl) 2017-01-31
US20090238821A1 (en) 2009-09-24
CN104341500A (zh) 2015-02-11
CA2400559A1 (en) 2001-08-30
JP4914412B2 (ja) 2012-04-11
EP3070100A1 (en) 2016-09-21
CZ306683B6 (cs) 2017-05-03
IL193631A (en) 2010-11-30
IL193631A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
US7892545B2 (en) Humanized antibodies that sequester amyloid beta peptide
AU2001241786B2 (en) Humanized antibodies that sequester abeta peptide
AU2006249277B2 (en) Humanized antibodies that sequester amyloid beta peptide
HK1048640C (en) Humanized antibodies that sequester amyloid beta peptide
HK1071145A (en) Humanized antibodies that sequester amyloid beta peptide
AU2001241786A1 (en) Humanized antibodies that sequester abeta peptide